\
&
Contact us
\
&
Contact us
This was 1 year ago
Locationvirtual
ProgrammesThe ERC Executive Agency organizes a second webinar for applicants to the ERC Advanced Grant 2024 call (call deadline 29 August 2022):
Are you preparing your application to the ERC Advanced Grant 2024 call to be submitted before the 29 August deadline? Assisting a Principal Investigator in their proposal preparation? Having doubts about how to fill in the new lump sum budget forms? Any other problem? This webinar is for you.
On the final stretch of the Advanced Grant 2024 application period, our call coordinators and lump sums experts will guide you over the submission process and answer your practical questions online.
Useful links and documents
Before the webinar, you may find useful to check the official information, the answers to most of the questions that applicants have asked us so far, and our previous webinar focused on lump sums.
For more personalised help, you can always send your question to ERC-2024-ADG-APPLICANTS@ec.europa.eu
For this webinar no registration is needed. All information related to this webinar and the Webex connection details can be found in this announcement on the ERC website.
We offer news and event updates, covering all domains and topics of Horizon Europe, Digital Europe & EDF (and occasionally, for ongoing projects, Horizon 2020).
Stay informed about what matters to you.
By signing up, you can opt in for e-mail notifications and get access to
a personalised dashboard that groups all news updates and event announcements in your domain(s).
Only for stakeholders located in Flanders
The METHYLOMIC project, ‘targeting hope for personalised medicine in immune-mediated inflammatory diseases’ obtained funding from Horizon Europe’s Health Cluster. The project aims to personalise treatment allocation and enhance the effectiveness of medications for chronic immune-mediated diseases such as Crohn’s disease, rheumatoid arthritis, and psoriasis. BIRD, the Belgian inflammatory bowel disease research and development group, is a partner in the project and is involved in the OmiCrohn trial, a prospective randomised clinical trial for individualised therapy in Crohn’s disease patients. With BIRD’s active role in this trial, the project is set to deliver predictive, biomarker-based therapies that bring renewed hope for Crohn’s disease patients across Europe.
